Logo

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

Share this

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive CHMP's Positive Opinion as 1L Treatment for Advanced Renal Cell Carcinoma

Shots:

  • The CHMP recommendation is based on P-III CheckMate -9ER trial involves assessing Opdivo + Cabometyx vs sunitinib in 651 patients with previously untreated advanced or metastatic RCC
  • The P-III result showed improvements in PFS- OS and ORR with consistent efficacy benefits observed across key subgroups of patients and was well tolerated- with a low rate of treatment-related discontinuations
  • The EC has the authority to approve medicines for the EU and now review the CHMP recommendation. The findings were presented at Presidential Symposium at the ESMO Virtual Congress 2020

 ­ Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions